Cargando…

The Bioequivalence of Emulsified Isoflurane With a New Formulation of Emulsion: A Single-Center, Single-Dose, Double-Blinded, Randomized, Two-Period Crossover Study

Background: Emulsified isoflurane is a novel intravenous general anesthetic obtained by encapsulating isoflurane molecules into emulsion. The formulation of emulsion has been improved according to the latest regulations of the China Food and Drug Administration. This study was designed to compare th...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Hui, Yin, Qinqin, Huang, Luying, Zhang, Min, Zhang, Xinxin, Sun, Qirong, Liu, Xuewei, Wang, Qi, Yang, Xi, Tan, Lingcan, Ye, Mao, Liu, Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7988084/
https://www.ncbi.nlm.nih.gov/pubmed/33776768
http://dx.doi.org/10.3389/fphar.2021.626307
_version_ 1783668719837249536
author Yang, Hui
Yin, Qinqin
Huang, Luying
Zhang, Min
Zhang, Xinxin
Sun, Qirong
Liu, Xuewei
Wang, Qi
Yang, Xi
Tan, Lingcan
Ye, Mao
Liu, Jin
author_facet Yang, Hui
Yin, Qinqin
Huang, Luying
Zhang, Min
Zhang, Xinxin
Sun, Qirong
Liu, Xuewei
Wang, Qi
Yang, Xi
Tan, Lingcan
Ye, Mao
Liu, Jin
author_sort Yang, Hui
collection PubMed
description Background: Emulsified isoflurane is a novel intravenous general anesthetic obtained by encapsulating isoflurane molecules into emulsion. The formulation of emulsion has been improved according to the latest regulations of the China Food and Drug Administration. This study was designed to compare the bioequivalence of the new and previous formulation emulsion of isoflurane. Methods: In a single-center, single-dose, double-blinded, randomized, two-period crossover study, healthy volunteers received intravenous injection of 30 mg/kg of isoflurane with either previous formulation of emulsion isoflurane (PFEI) or new formulation of emulsion isoflurane (NFEI). Arterial and venous blood samples were obtained for geometric mean test/reference ratios of C(max), AUC(0-t), and AUC(0-∞,) as well as their 90% confidence interval (CI90) as the primary outcome. The secondary outcomes were safety measurements such as vital signs, 12-lead electrocardiography, adverse effects, and laboratory tests; and anesthesia efficacy was assessed by Modified Observer’s Assessment of Alertness/Sedation (MOAA/S) score, bispectral index (BIS), and loss/recovery of eyelash reflex. Results: 24 subjects were eligible, of which 21 completed the whole experiment (NFEI n = 21, PFEI n = 23). Arterial geometric mean test/reference ratios of C(max), AUC(0-t), and AUC(0-∞) were 104.50% (CI90 92.81%–117.65%), 108.23% (94.51%–123.96%), and 106.53% (93.94%∼120.80%), respectively. The most commonly seen adverse effects for NFEI and PFEI were injection pain (38.1% vs. 34.8%), hypotension (19.0% vs. 13.0%), apnea (14.3% vs. 17.4%), and upper airway obstruction (14.3% vs. 13.0%). No severe adverse effect was observed. The effectiveness of general anesthesia was similar between the two formulations. Conclusion: The CI90 of C(max), AUC(0-t), AUC(0-∞), NFEI, and PFEI were within the range of 80%–125%, suggesting bioequivalence between NFEI and PFEI. The safety and anesthesia effectiveness were also similar.
format Online
Article
Text
id pubmed-7988084
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-79880842021-03-25 The Bioequivalence of Emulsified Isoflurane With a New Formulation of Emulsion: A Single-Center, Single-Dose, Double-Blinded, Randomized, Two-Period Crossover Study Yang, Hui Yin, Qinqin Huang, Luying Zhang, Min Zhang, Xinxin Sun, Qirong Liu, Xuewei Wang, Qi Yang, Xi Tan, Lingcan Ye, Mao Liu, Jin Front Pharmacol Pharmacology Background: Emulsified isoflurane is a novel intravenous general anesthetic obtained by encapsulating isoflurane molecules into emulsion. The formulation of emulsion has been improved according to the latest regulations of the China Food and Drug Administration. This study was designed to compare the bioequivalence of the new and previous formulation emulsion of isoflurane. Methods: In a single-center, single-dose, double-blinded, randomized, two-period crossover study, healthy volunteers received intravenous injection of 30 mg/kg of isoflurane with either previous formulation of emulsion isoflurane (PFEI) or new formulation of emulsion isoflurane (NFEI). Arterial and venous blood samples were obtained for geometric mean test/reference ratios of C(max), AUC(0-t), and AUC(0-∞,) as well as their 90% confidence interval (CI90) as the primary outcome. The secondary outcomes were safety measurements such as vital signs, 12-lead electrocardiography, adverse effects, and laboratory tests; and anesthesia efficacy was assessed by Modified Observer’s Assessment of Alertness/Sedation (MOAA/S) score, bispectral index (BIS), and loss/recovery of eyelash reflex. Results: 24 subjects were eligible, of which 21 completed the whole experiment (NFEI n = 21, PFEI n = 23). Arterial geometric mean test/reference ratios of C(max), AUC(0-t), and AUC(0-∞) were 104.50% (CI90 92.81%–117.65%), 108.23% (94.51%–123.96%), and 106.53% (93.94%∼120.80%), respectively. The most commonly seen adverse effects for NFEI and PFEI were injection pain (38.1% vs. 34.8%), hypotension (19.0% vs. 13.0%), apnea (14.3% vs. 17.4%), and upper airway obstruction (14.3% vs. 13.0%). No severe adverse effect was observed. The effectiveness of general anesthesia was similar between the two formulations. Conclusion: The CI90 of C(max), AUC(0-t), AUC(0-∞), NFEI, and PFEI were within the range of 80%–125%, suggesting bioequivalence between NFEI and PFEI. The safety and anesthesia effectiveness were also similar. Frontiers Media S.A. 2021-03-10 /pmc/articles/PMC7988084/ /pubmed/33776768 http://dx.doi.org/10.3389/fphar.2021.626307 Text en Copyright © 2021 Yang, Yin, Huang, Zhang, Zhang, Sun, Liu, Wang, Yang, Tan, Ye and Liu. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Yang, Hui
Yin, Qinqin
Huang, Luying
Zhang, Min
Zhang, Xinxin
Sun, Qirong
Liu, Xuewei
Wang, Qi
Yang, Xi
Tan, Lingcan
Ye, Mao
Liu, Jin
The Bioequivalence of Emulsified Isoflurane With a New Formulation of Emulsion: A Single-Center, Single-Dose, Double-Blinded, Randomized, Two-Period Crossover Study
title The Bioequivalence of Emulsified Isoflurane With a New Formulation of Emulsion: A Single-Center, Single-Dose, Double-Blinded, Randomized, Two-Period Crossover Study
title_full The Bioequivalence of Emulsified Isoflurane With a New Formulation of Emulsion: A Single-Center, Single-Dose, Double-Blinded, Randomized, Two-Period Crossover Study
title_fullStr The Bioequivalence of Emulsified Isoflurane With a New Formulation of Emulsion: A Single-Center, Single-Dose, Double-Blinded, Randomized, Two-Period Crossover Study
title_full_unstemmed The Bioequivalence of Emulsified Isoflurane With a New Formulation of Emulsion: A Single-Center, Single-Dose, Double-Blinded, Randomized, Two-Period Crossover Study
title_short The Bioequivalence of Emulsified Isoflurane With a New Formulation of Emulsion: A Single-Center, Single-Dose, Double-Blinded, Randomized, Two-Period Crossover Study
title_sort bioequivalence of emulsified isoflurane with a new formulation of emulsion: a single-center, single-dose, double-blinded, randomized, two-period crossover study
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7988084/
https://www.ncbi.nlm.nih.gov/pubmed/33776768
http://dx.doi.org/10.3389/fphar.2021.626307
work_keys_str_mv AT yanghui thebioequivalenceofemulsifiedisofluranewithanewformulationofemulsionasinglecentersingledosedoubleblindedrandomizedtwoperiodcrossoverstudy
AT yinqinqin thebioequivalenceofemulsifiedisofluranewithanewformulationofemulsionasinglecentersingledosedoubleblindedrandomizedtwoperiodcrossoverstudy
AT huangluying thebioequivalenceofemulsifiedisofluranewithanewformulationofemulsionasinglecentersingledosedoubleblindedrandomizedtwoperiodcrossoverstudy
AT zhangmin thebioequivalenceofemulsifiedisofluranewithanewformulationofemulsionasinglecentersingledosedoubleblindedrandomizedtwoperiodcrossoverstudy
AT zhangxinxin thebioequivalenceofemulsifiedisofluranewithanewformulationofemulsionasinglecentersingledosedoubleblindedrandomizedtwoperiodcrossoverstudy
AT sunqirong thebioequivalenceofemulsifiedisofluranewithanewformulationofemulsionasinglecentersingledosedoubleblindedrandomizedtwoperiodcrossoverstudy
AT liuxuewei thebioequivalenceofemulsifiedisofluranewithanewformulationofemulsionasinglecentersingledosedoubleblindedrandomizedtwoperiodcrossoverstudy
AT wangqi thebioequivalenceofemulsifiedisofluranewithanewformulationofemulsionasinglecentersingledosedoubleblindedrandomizedtwoperiodcrossoverstudy
AT yangxi thebioequivalenceofemulsifiedisofluranewithanewformulationofemulsionasinglecentersingledosedoubleblindedrandomizedtwoperiodcrossoverstudy
AT tanlingcan thebioequivalenceofemulsifiedisofluranewithanewformulationofemulsionasinglecentersingledosedoubleblindedrandomizedtwoperiodcrossoverstudy
AT yemao thebioequivalenceofemulsifiedisofluranewithanewformulationofemulsionasinglecentersingledosedoubleblindedrandomizedtwoperiodcrossoverstudy
AT liujin thebioequivalenceofemulsifiedisofluranewithanewformulationofemulsionasinglecentersingledosedoubleblindedrandomizedtwoperiodcrossoverstudy
AT yanghui bioequivalenceofemulsifiedisofluranewithanewformulationofemulsionasinglecentersingledosedoubleblindedrandomizedtwoperiodcrossoverstudy
AT yinqinqin bioequivalenceofemulsifiedisofluranewithanewformulationofemulsionasinglecentersingledosedoubleblindedrandomizedtwoperiodcrossoverstudy
AT huangluying bioequivalenceofemulsifiedisofluranewithanewformulationofemulsionasinglecentersingledosedoubleblindedrandomizedtwoperiodcrossoverstudy
AT zhangmin bioequivalenceofemulsifiedisofluranewithanewformulationofemulsionasinglecentersingledosedoubleblindedrandomizedtwoperiodcrossoverstudy
AT zhangxinxin bioequivalenceofemulsifiedisofluranewithanewformulationofemulsionasinglecentersingledosedoubleblindedrandomizedtwoperiodcrossoverstudy
AT sunqirong bioequivalenceofemulsifiedisofluranewithanewformulationofemulsionasinglecentersingledosedoubleblindedrandomizedtwoperiodcrossoverstudy
AT liuxuewei bioequivalenceofemulsifiedisofluranewithanewformulationofemulsionasinglecentersingledosedoubleblindedrandomizedtwoperiodcrossoverstudy
AT wangqi bioequivalenceofemulsifiedisofluranewithanewformulationofemulsionasinglecentersingledosedoubleblindedrandomizedtwoperiodcrossoverstudy
AT yangxi bioequivalenceofemulsifiedisofluranewithanewformulationofemulsionasinglecentersingledosedoubleblindedrandomizedtwoperiodcrossoverstudy
AT tanlingcan bioequivalenceofemulsifiedisofluranewithanewformulationofemulsionasinglecentersingledosedoubleblindedrandomizedtwoperiodcrossoverstudy
AT yemao bioequivalenceofemulsifiedisofluranewithanewformulationofemulsionasinglecentersingledosedoubleblindedrandomizedtwoperiodcrossoverstudy
AT liujin bioequivalenceofemulsifiedisofluranewithanewformulationofemulsionasinglecentersingledosedoubleblindedrandomizedtwoperiodcrossoverstudy